Home » Stocks » LABP

Landos Biopharma, Inc. (LABP)

Stock Price: $10.59 USD -0.92 (-7.99%)
Updated Apr 19, 2021 2:00 PM EDT - Market open
Market Cap 414.74M
Revenue (ttm) n/a
Net Income (ttm) -30.14M
Shares Out 39.16M
EPS (ttm) -0.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $10.59
Previous Close $11.51
Change ($) -0.92
Change (%) -7.99%
Day's Open 11.50
Day's Range 10.45 - 11.50
Day's Volume 20,376
52-Week Range 8.82 - 16.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BLACKSBURG, Va., April 13, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with...

6 days ago - GlobeNewsWire

The FDA has signed off Landos Biopharma's (NASDAQ: LABP) Investigational New Drug application for omilancor (BT-11) for the treatment of Eosinophilic Esophagitis (EoE). Landos expects to initiate patien...

1 week ago - Benzinga

Third potential indication for omilancor (BT-11), a first-in-class candidate for the treatment of autoimmune diseases Third potential indication for omilancor (BT-11), a first-in-class candidate for the...

1 week ago - GlobeNewsWire

NX-13 was well tolerated with no reported serious adverse events

1 month ago - GlobeNewsWire

BLACKSBURG, Va., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (Nasdaq: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with ...

1 month ago - GlobeNewsWire

BLACKSBURG, Va., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune dise...

2 months ago - GlobeNewsWire

Xontogeny’s Landos Biopharma is jumping into warm biotech IPO waters as it looks to go public with a $100 million offering.

3 months ago - FierceBiotech

On January 4, the company announced slightly murky data from its first-in-patients 12-week Phase II proof-of-concept trial of BT-11 for mild to moderate ulcerative colitis.

3 months ago - BioSpace

Landos Biopharma, a Phase 2 biotech developing oral small molecule therapies for autoimmune diseases, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.

3 months ago - NASDAQ

Landos Biopharma, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC

About LABP

Landos Biopharma is a clinical-stage biopharmaceutical company developing novel, disease-specific oral therapeutic candidates designed to address the therapeutic gap in the current treatment paradigm for autoimmune diseases.. We believe the therapeutics we discover and develop, if approved, will have a significant impact on the quality of life of patients suffering from autoimmune diseases. While great strides have been made, existing approaches continue to leave patient needs unmet, due in part to significant safety concerns. Our core experti... [Read more...]

Industry
Biotechnology
IPO Date
Feb 4, 2021
CEO
Josep Bassaganya-Riera
Employees
33
Stock Exchange
NASDAQ
Ticker Symbol
LABP
Full Company Profile

Financial Performance

Financial Statements